Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial
Authors:
- Alexander L. GerbesAlexander L. Gerbes
- Veit GülbergVGVeit Gülberg
- Pere GinèsPGPere Ginès
- Guy DecauxGDGuy Decaux
- Peter GrossPGPeter Gross
- Hassan GandjiniHGHassan Gandjini
- Jacques DjianJDJacques Djian
- 1 April 2003
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 124 (4) , 933-939
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- A prognostic model for predicting survival in cirrhosis with ascitesJournal of Hepatology, 2001
- Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patientsDigestive and Liver Disease, 2000
- HyponatremiaNew England Journal of Medicine, 2000
- Hyponatremia in cirrhosis: From pathogenesis to treatment†Hepatology, 1998
- Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosisJournal of Hepatology, 1996
- Medical treatment of ascites in cirrhosisJournal of Hepatology, 1993
- Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascitesGastroenterology, 1993
- Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonistBritish Journal of Pharmacology, 1992
- Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascitesGastroenterology, 1988
- Prognostic value of spontaneous hyponatremia in cirrhosis with ascitesDigestive Diseases and Sciences, 1976